Sei Investments Co. Has $9.61 Million Stake in Organon & Co. (NYSE:OGN)

Sei Investments Co. lowered its position in Organon & Co. (NYSE:OGN - Free Report) by 6.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 644,136 shares of the company's stock after selling 43,155 shares during the period. Sei Investments Co. owned 0.25% of Organon & Co. worth $9,610,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. increased its stake in shares of Organon & Co. by 94,482.1% during the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock worth $166,391,000 after purchasing an additional 11,140,388 shares during the last quarter. Weiss Asset Management LP bought a new stake in Organon & Co. in the third quarter worth $32,966,000. Magnetar Financial LLC increased its position in Organon & Co. by 560.2% during the fourth quarter. Magnetar Financial LLC now owns 1,734,434 shares of the company's stock worth $25,878,000 after buying an additional 1,471,731 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in Organon & Co. by 303.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company's stock valued at $23,762,000 after buying an additional 934,505 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Organon & Co. by 191.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 760,807 shares of the company's stock valued at $11,382,000 after buying an additional 499,616 shares in the last quarter. Institutional investors own 77.43% of the company's stock.

Remove Ads

Organon & Co. Price Performance

OGN stock traded down $0.30 during trading on Thursday, hitting $14.42. The company had a trading volume of 3,051,888 shares, compared to its average volume of 2,559,335. The company has a fifty day moving average price of $15.22 and a two-hundred day moving average price of $16.10. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The company has a market cap of $3.72 billion, a P/E ratio of 4.33, a P/E/G ratio of 0.90 and a beta of 0.76. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Equities research analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a dividend of $0.28 per share. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.77%. Organon & Co.'s dividend payout ratio (DPR) is presently 33.63%.

Analysts Set New Price Targets

A number of research analysts have recently commented on OGN shares. Barclays lowered their price objective on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. TD Cowen upgraded Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Finally, Morgan Stanley reduced their price objective on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a research report on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.